SEATTLE--(

--(

BUSINESS WIRE

商业热线

)--Tasso, Inc., the leading provider of patient-centric, clinical grade blood collection solutions, today announced the launch of its next generation technology for dried blood spot (DBS) sample collection. The novel collection system combines Tasso’s new Tile™-T20 dried whole blood cartridge with a Tasso™ Mini device, enabling the precise, convenient collection of DBS samples for clinical trials and sports anti-doping testing..

)--以患者为中心的临床级血液采集解决方案的领先供应商Tasso，Inc.今天宣布推出其下一代干血斑（DBS）样本采集技术。新型采集系统将Tasso的新型Tile™T20干全血盒与Tasso™微型设备结合在一起，可以精确、方便地采集DBS样本，用于临床试验和体育反兴奋剂测试。。

Tasso’s new collection system provides advantages over legacy DBS methods, improving and accelerating the clinical trial process. Tile-T20 is the first DBS collection cartridge designed specifically for use with patient-centric blood lancets. Tile-T20 collects four precise, volumetrically-controlled blood samples that meet the needs of quantitative endpoints or drug concentration measurements.

Tasso的新采集系统提供了优于传统DBS方法的优势，改善并加速了临床试验过程。Tile-T20是第一个专门设计用于以患者为中心的血矛的DBS采集墨盒。Tile-T20收集四个精确的，体积控制的血液样本，满足定量终点或药物浓度测量的需要。

It is compatible with any of Tasso’s virtually painless, FDA-cleared and CE Marked blood collection devices, including Tasso Mini and Tasso+®..

它与任何Tasso的几乎无痛，FDA批准和CE标记的血液采集设备兼容，包括Tasso Mini和Tasso+®。。

Tasso Mini

Tasso 迷你

is the latest device in Tasso’s signature line of patient-centric blood lancets, providing a gentle collection experience ideal for use with sensitive populations or for applications that may require more frequent blood draws. The Tasso Mini device is FDA Class II Lancet 510(k)-cleared and CE Marked..

是Tasso以患者为中心的血液柳叶刀标志系列中的最新设备，为敏感人群或可能需要更频繁抽血的应用提供了温和的采集体验。Tasso Mini设备是FDA II级柳叶刀510（k）-清除和CE标记的。。

“Dried blood samples offer many advantages for clinical trials and remote applications, but collection methods have long been a burden on patients, relying on painful finger sticks and messy blood spotting to obtain samples,” said Ben Casavant, PhD, CEO and Co-Founder of Tasso. “Our next generation dried blood collection systems enable a better patient experience alongside new process improvements.”.

Tasso首席执行官兼联合创始人Ben Casavant博士说：“干血样本为临床试验和远程应用提供了许多优势，但采集方法长期以来一直是患者的负担，依靠痛苦的手指棒和混乱的血液斑点来获取样本。”。“我们的下一代干血采集系统能够在改进新流程的同时，为患者带来更好的体验。”。

“Access to clinic sites can be difficult for many patients, especially for those without reliable transportation or living in rural areas. Unfortunately, access challenges often lead to recruitment and retention issues, ultimately delaying clinical trial timelines,” said Erwin Berthier, PhD, CTO and Co-Founder of Tasso.

。

“This new technology has the potential to improve trial timelines and speed new therapies to patients in need.”.

“这项新技术有可能改进试验时间表，并为有需要的患者加速新疗法。”。

To learn more about Tasso’s dried blood collection solutions, please visit

要了解更多有关塔索干血采集解决方案的信息，请访问

www.tassoinc.com/dried-blood

.

.

About Tasso

关于塔索

Tasso is an emerging healthcare technology company that is transforming the traditional blood collection paradigm with a patient-centric approach. The company’s devices enable simple, convenient, and virtually painless blood collection for users. Tasso technology has the power to bring healthcare anywhere, any time.

Tasso是一家新兴的医疗保健技术公司，正在以患者为中心的方法改变传统的采血模式。该公司的设备为用户提供了简单、方便、几乎无痛的血液采集。Tasso技术有能力随时随地提供医疗保健。

Headquartered in Seattle, Washington, Tasso is privately held and funded by grants, investments, and co-development deals with various industry leaders. For more information, please visit .

塔索总部位于华盛顿州西雅图，是一家私营企业，通过赠款、投资以及与各行业领导者的共同开发协议提供资金。有关更多信息，请访问。

www.tassoinc.com

www.tassoinc.com

.

.